Data Sheet (Cat.No.TMPK-00338)

TargetMol

LRRC15 Protein, Human, Recombinant (His & Avi)

General Information

Synonyms:	LRRC15;LIB
Protein Construction:	Tyr22-Gly538
Species:	Human
Expression Host:	CHO Cells
Accession:	Q8TF66-1
Molecular Weight:	60.7 kDa (predicted). Due to glycosylation, the protein migrates to 70-80 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Human LRRC15, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LRRC15 Antibody, hFc Tag with the EC50 of 11.1ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM Tris, 120 mM NaCl (pH 7.5). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to

abrogation of invasiveness in vitro.

Reference

Kobayashi I, et al. Dual role of Jam3b in early hematopoietic and vascular development. Development. 2020;147 (1):dev181040. Published 2020 Jan 8. doi:10.1242/dev.181040

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481